AB Science webcast of May 30, 2024
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS
Corrective statement on the consolidated accounts as of December 31, 2023
17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023
Annual financial results as of 31 December, 2023
15/05/2024 – AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patients
07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
02/05/2024 – AB Science announced today that the Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
AB Science announces a slight delay in the publication of its 2023 annual financial report
30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS)
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases